Evaluation of Clinical Outcomes Associated With Phenobarbital With Taper Compared to No Taper for the Management of Alcohol Withdrawal Syndrome

被引:0
|
作者
Thaller, Matthew [1 ]
Wong, Adrian [1 ]
Yankama, Tuyen [1 ]
Eche, Ifeoma Mary [1 ]
Elsamadisi, Pansy [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Pharm, One Deaconess Rd, Boston, MA 02215 USA
关键词
barbiturates; drug; alcohol; and substance use; withdrawal; sedatives; critical care; drug interactions; SCALE;
D O I
10.1177/10600280241236412
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Phenobarbital (PHB) has been shown to be an effective treatment of alcohol withdrawal syndrome (AWS), with multiple dosing strategies used (e.g., single-dose and symptom-triggered). Studies have often used tapered doses, typically following a front-loaded dose, despite PHB's long half-life which should lead to an ability to auto-taper.Objective: The purpose of this study was to compare clinical outcomes associated with two PHB dosing strategies (taper [T], no taper [NT]) for AWS.Methods: This retrospective cohort study compared adult patients admitted to the ICU from October 2017 to May 2019 who received an initial loading dose of PHB for AWS. The use of PHB was at the discretion of the clinician per our institutional guidelines. Prior to November 2018, patients were prescribed a PHB taper, while after this period, the taper was no longer recommended. The primary outcome was the proportion of patients requiring rescue PHB or adjunctive medications for AWS. Secondary outcomes included number of adjunctive agents used, prevalence of severe manifestations of AWS, ICU and hospital lengths of stay, and incidence of potentially significant drug interactions.Results: A total of 172 patients were included (T: n = 81, NT: n = 91). Baseline characteristics were similar between groups, including history of severe AWS and cumulative benzodiazepine dose pre-PHB. There was no difference in the primary outcome between groups (T: 70.4% vs NT: 59.3%, P = 0.152). The median number of adjunctive agents per patient, severe manifestations, and ICU and hospital length of stay did not differ between groups. Twenty-five patients (14.5%) had potentially significant drug interactions.Conclusion and Relevance: The use of a PHB loading dose without a taper may be comparable to a taper strategy on clinical outcomes. Prospective studies are needed to further delineate the optimal dose of PHB for AWS.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Phenobarbital for the Management of Alcohol Withdrawal Syndrome in Critically Ill, Surgical-Trauma Patients
    Pham, Christine
    Goldenberg-Sandau, Anna
    Sensenig, Rachel
    Chau, Terence
    Igneri, Lauren
    Solomon, Diana
    Chuang, Linda
    [J]. JOURNAL OF SURGICAL RESEARCH, 2023, 283 : 965 - 972
  • [32] Concerns Regarding the Use of Phenobarbital for Alcohol Withdrawal Management
    Azadfard, Mohammadreza
    Danzi, Bryan
    [J]. PSYCHOSOMATICS, 2020, 61 (06) : 861 - 863
  • [33] EVALUATION OF PHENOBARBITAL FOR PREVENTION OF ALCOHOL WITHDRAWAL IN TRAUMA PATIENTS
    Kip, Lindsey
    Forni, Allison
    Dorfman, Jon
    Li, Irene
    [J]. CRITICAL CARE MEDICINE, 2023, 51 (01) : 643 - 643
  • [34] CLINICAL OUTCOMES OF ADJUNCTIVE KETAMINE FOR MANAGING ALCOHOL WITHDRAWAL SYNDROME
    Armahizer, Michael
    Wong, Adrian
    Benedict, Neal
    Kane-Gill, Sandra
    [J]. CRITICAL CARE MEDICINE, 2014, 42 (12)
  • [35] Evaluation of phenobarbital for prevention of alcohol withdrawal in trauma patients
    Kip, Lindsey Marie
    Forni, Allison
    Dorfman, Jon David
    Li, Irene
    [J]. JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2023, 95 (04): : 573 - 576
  • [36] Patient outcomes for phenobarbital use with or without benzodiazepines in alcohol withdrawal syndrome: systematic review.
    Rowe, Jordan
    Hammond, Drayton
    Wiley, Tessa
    Lee, Kristen
    Kane-Gill, Sandra
    [J]. PHARMACOTHERAPY, 2016, 36 (12): : E301 - E302
  • [37] Management of Alcohol Withdrawal Syndrome
    Ricks, Janet
    Replogle, William H.
    Cook, Nakia Joye
    [J]. AMERICAN FAMILY PHYSICIAN, 2010, 82 (04) : 344 - +
  • [38] Alcohol withdrawal syndrome management
    Couzigou, P
    Ledinghen, V
    [J]. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2002, 26 (05): : B163 - B168
  • [39] PHARMACOKINETIC DOSING OF PHENOBARBITAL IN THE TREATMENT OF ALCOHOL-WITHDRAWAL SYNDROME
    IVES, TJ
    MOONEY, AJ
    GWYTHER, RE
    [J]. SOUTHERN MEDICAL JOURNAL, 1991, 84 (01) : 18 - 20
  • [40] The Effect of Phenobarbital on Excitatory Transmission in Alcohol Withdrawal Syndrome Reply
    Gottlieb, Michael
    Chien, Nicholas
    Long, Brit
    [J]. ANNALS OF EMERGENCY MEDICINE, 2024, 84 (03) : 328 - 329